Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.

EFX is now being further evaluated in three ongoing Phase 3 trials targeting all stages of MASH. EFX, Akero's lead candidate, is an FGF21 analog designed for once-weekly dosing.

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...